北京医改控费显成效 药品采购预计省30亿元

2017-09-27 佚名 中国新闻网

今年4月8日起北京实施医药分开综合改革,截至目前总体平稳有序,各方反响良好。其中,药费和药占比、二三级医院诊疗量、大型设备检查费、医保患者负担持续“五下降”。仅药品阳光采购一项,预计今年可节省药品费用30亿元以上,高于预期。

今年4月8日起北京实施医药分开综合改革,截至目前总体平稳有序,各方反响良好。其中,药费和药占比、二三级医院诊疗量、大型设备检查费、医保患者负担持续“五下降”。仅药品阳光采购一项,预计今年可节省药品费用30亿元以上,高于预期。

多部门联动,加强综合管理

今天,记者从北京市卫生计生委了解到,为确保医改的顺利实施,北京建立多部门联动的工作机制,围绕医疗、医药、医保制定了近30个改革文件,包括取消医疗机构药品加成,实行零差率销售;取消挂号费、诊疗费,设立医事服务费,体现医务人员技术劳动价值;实施药品阳光采购,挤压药品价格的虚高空间;按有升有降和发展短板原则规范调整435项基本医疗服务项目及价格,使价格反映成本等政策措施,还包括促进分级诊疗制度建设,改善医疗服务,加强综合监管,改革医保支付方式等综合改革措施。

促进分级诊疗,理顺就医秩序

此次医改的一个重大举措就是分级按职称设置医事服务费,释放明确的引导基层首诊的价格信号,调整医保报销政策,向基层倾斜,促进分级诊疗制度建设。

数据显示,四个多月来,与去年同期相比,三级医院、二级医院门急诊量分别减少12.5%和5%,一级医院及基层医疗卫生机构增加11.5%,城区部分社区卫生服务机构诊疗量增加20%左右。一些普通病常见病逐步分流到基层机构。

门急诊中副主任医师、主任医师号就诊人次分别减少9.9%和22.8%,看专家难的问题有了缓解,有限的专家名医资源能更好地服务于危重急难患者,而三级医院更加注重住院服务提供,平均住院日明显缩短,服务效率改善。

控费成效显现,费用稳中有降

医改实施四个多月以来,数据显示,北京市医药费用仅增长2.2%,剔除上半年全市居民消费物价指数2%涨幅后接近零增长。药品阳光采购金额累计206.4亿元,共节省药品费用16.4亿元,药品价格在取消15%加成的基础上,平均下降超过8%。仅药品阳光采购一项,预计今年可节省药品费用30亿元以上,高于预期。

二、三级医院药占比由去年同期的42%下降到34%,且仍在下降。门急诊次均药费与去年同期相比三级、二级医院分别减少了7.4%和9.8%,一级医院和基层医疗卫生机构增加5.4%。住院例均药费在三级、二级和一级医院基层医疗卫生机构分别减少了17.7%、15.9%和17.2%。

提升保障水平,加强救助力度

此次医改中,北京加强城乡医疗保险和医疗救助力度,将医事服务费纳入城镇职工、城乡居民基本医疗保险和生育保险报销范围,并针对长期住院的精神病人等调整报销政策,实施按床日付费,并规定了支付上限,减轻个人负担,为改革提供支撑和保障。

其中,把社会救助对象的报销比例提高10个百分点,封顶线提高50%,医保患者和困难民众得到有效保障。

改革以来,城乡医疗保险患者个人负担总体下降,社会救助对象门诊、住院和重大疾病救助人均负担均减少了30%左右,社会保障制度发挥了重要的支撑作用。

消除逐利机制,突出公共利益

北京市卫计委表示,保护和调动各方参与改革的积极性,将改革的方向和原则要求与各方面的利益诉求有机结合,追求公共利益最大化。通过取消药品加成和设立医事服务费及规范医疗服务项目,消除了医疗机构追求药品收入的逐利机制,为加强公益性奠定了良好基础,新的补偿机制得以建立并发挥作用。

监测表明,医事服务费可置换原来的挂号费、诊疗费、药品加成收入,医疗机构收入含金量提高。与去年同期相比,医疗机构2017年6月可分配收入增长21.9%。

与此同时,通过规范医疗服务项目和收费,解决了一部分医疗服务项目收费显着低于成本的问题,中医、儿科、妇产、护理、传染等部分短板专业得到发展支撑。

北京市卫计委表示,下一步将持续深化医药卫生体制改革,推进健康北京建设,为民众提供更加安全、有效、方便、价廉的医疗卫生服务,持续改善居民健康水平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 1e1b8538m79(暂无匿称)

    不错啊文章值得一读.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 tidiq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1973730, encodeId=c08e19e37305b, content=<a href='/topic/show?id=67ec3362338' target=_blank style='color:#2F92EE;'>#北京医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33623, encryptionId=67ec3362338, topicName=北京医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 22:24:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248905, encodeId=7b9d248905c5, content=不错啊文章值得一读., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 29 22:21:38 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286837, encodeId=c7db128683e83, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532717, encodeId=8cb11532e177a, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537786, encodeId=3619153e78684, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623460, encodeId=21b416234606e, content=<a href='/topic/show?id=e85556e57f5' target=_blank style='color:#2F92EE;'>#控费#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56757, encryptionId=e85556e57f5, topicName=控费)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5ae20523392, createdName=jml2016, createdTime=Fri Sep 29 13:24:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 jml2016

相关资讯

“两寻找”第二站!优质资源下沉如何接地气、有底气?各路专家有话说!

如果有人要说“浙江名片”,大多数人都会想到西湖风光、温州经济、义乌制造、绍兴文化以及杭州智慧。而如今,浙江医改,俨然已成为一道靓丽风景线,星光熠熠,出现在大家的面前,长兴、嵊州、海盐作为国家级医改示范县和省级医改示范县,成为浙江医改“双下沉”中的翘楚。而嵊州更是以“最美医院”享誉四方。9月24-25日,助力优质医疗资源下沉高峰论坛暨“两寻找”项目第二站——浙江嵊州站活动在浙江省嵊州市人民医院举行。

又投3.22亿!广东建覆盖全省的远程医疗体系

该项目第一期将建设远程医疗系统,联接20家三级甲等医院和粤东西北56家县级医院,开展远程会诊、远程病理诊断、影像诊断、心电诊断、监护指导、手术指导、远程教育等。

医改路上的“盐池智慧”

前不久,宁夏回族自治区盐池县高沙窝镇村民李旭患阑尾炎住进了县人民医院治疗,从住院做手术到出院,费用报销80%,最后他只付了520元。在盐池县,看病便宜正吸引越来越多的患者留在县内治疗。盐池县副县长马瑞英说,这得益于该县2010年开始创新支付制度改革。

山西医改还需加强内部管理和改革评估

山西县乡一体化医疗改革促进了资源整合,优质资源下沉,提升了服务质量,是适应当前我国中西部社会特征的供给改革的新模式。

海南将新设立医疗保障管理局

海南将新设立医疗保障管理局,内设4个处级机构,负责全省医疗保障管理工作。

重庆:医改让群众吃上“定心丸”

全市门诊次均药品费用较改革前一周同比降低7.9%;门诊次均医疗费用减少10元;药占比下降2个百分点;患者满意度提高到96%……持续的监测数据表示,重庆市从9月9日开始的医改效果显现。